Incannex Healthcare (NASDAQ:IXHL - Get Free Report) issued its earnings results on Friday. The company reported ($0.02) EPS for the quarter, meeting analysts' consensus estimates of ($0.02...
MarketBeat·2d ago
More News
Incannex Healthcare (IXHL) Expected to Announce Quarterly Earnings on Friday
Incannex Healthcare (NASDAQ:IXHL) will be releasing its Q2 2026 earnings before the market opens on Friday, February 13. (View Earnings Report at...
MarketBeat·10d ago
Short Interest in Incannex Healthcare Inc. (NASDAQ:IXHL) Decreases By 30.9%
Incannex Healthcare Inc. (NASDAQ:IXHL - Get Free Report) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totaling 15,236,764 shares...
MarketBeat·29d ago
Incannex Healthcare (NASDAQ:IXHL) Trading Up 2.1% - Still a Buy?
Incannex Healthcare (NASDAQ:IXHL) Stock Price Up 2.1% - Time to Buy...
MarketBeat·1mo ago
Incannex Healthcare (NASDAQ:IXHL) Trading Down 8.8% - Here's What Happened
Incannex Healthcare (NASDAQ:IXHL) Trading Down 8.8% - Should You Sell...
MarketBeat·2mo ago
Penny Stocks To Keep An Eye On - December 3rd
iRobot, Richtech Robotics, Bitfarms, Virax Biolabs Group, Nauticus Robotics, Incannex Healthcare, and Fusion Fuel Green are the seven Penny stocks to watch today, according to MarketBeat's stock...
MarketBeat·2mo ago
Incannex Healthcare Stock Soars 15% After FDA Fast Tracks Obstructive Sleep Apnea Drug
Incannex’s Fast Track designation for IHL-42X follows strong Phase 2 data and grants the program expanded FDA access and review advantages.
Stocktwits·2mo ago
What Makes Incannex Healthcare Inc. (IXHL) a New Buy Stock
Incannex Healthcare Inc. (IXHL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·3mo ago
Incannex Healthcare (NASDAQ:IXHL) Trading Up 1.1% - Still a Buy?
Incannex Healthcare (NASDAQ:IXHL) Shares Up 1.1% - Time to Buy...
MarketBeat·3mo ago
Incannex Healthcare Stock Sees Retail Chatter Explode 234% Over Last Week
The company is developing combination medicines for several chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalised anxiety disorder.